mhurhangee/ep-ind-claims huggingface dataset:
A method of detecting saturation in a transmit amplifier, the method comprising: transmitting a signal that includes information symbols and is in a format encoded with a non-constant envelope, said signal comprising a burst portion which includes a first dither part at a first power level and a second dither part at a second power level, having a known and definite difference between said first power level and said second power level where said difference defines a difference in power level greater than a normal transmission in said format; receiving from a remote receiver an indication to reduce an amount of power in said transmitting, responsive to said transmitting; and responsive to receiving said indication, taking an action to reduce an amount of saturation in said transmitting. transmitting a signal that includes information symbols and is in a format encoded with a non-constant envelope, said signal comprising a burst portion which includes a first dither part at a first power level and a second dither part at a second power level, having a known and definite difference between said first power level and said second power level where said difference defines a difference in power level greater than a normal transmission in said format; receiving from a remote receiver an indication to reduce an amount of power in said transmitting, responsive to said transmitting; and responsive to receiving said indication, taking an action to reduce an amount of saturation in said transmitting.
Wind turbine comprising a tower made up of longitudinal sections in turn comprising a plurality of voussoirs, wherein the voussoirs comprise an inner face, an outer face and at least one flank configured to be facing a flank of an adjacent voussoir so as to define a cavity, configured to be at least partially filled by a filler material, and each voussoir comprises at least one sealing element of elastomeric material that is configured to remain in contact with the flank of the adjacent voussoir closing the cavity laterally, the sealing element having a height, measured in a perpendicular direction to the flank, greater than the distance between the flank where said sealing element is located and the flank of the adjacent voussoir when they are joined; whereby each voussoir comprises two opposite flanks configured to be facing a flank of an adjacent voussoir and in each flank the voussoirs comprise a sealing element placed in contact with the inner face of the voussoir or placed in contact with the outer face of the voussoir and whereby the voussoirs are placed in such a way that a flank in which the sealing element is arranged in contact with the inner face is placed adjacent to a flank of an adjacent voussoir in which the sealing element is in contact with the outer face;; characterised in that each voussoir is configured to be arranged with a movement substantially parallel to the flank, so the sealing element is deformed in the direction of relative movement of the voussoir on which it is integrated.
A titanium slab for hot rolling characterized by being a titanium cast slab, in the longitudinal cross-sectional structure of which titanium slab the angle formed by the casting direction and the solidification direction is in the range of 45 to 90°; wherein the thickness of the titanium slab for hot rolling is 225 to 290 mm and ratio W/T of width W to thickness T is 2.5 to 8.0.
A composition for inhibiting influenza virus neuraminidase, the composition comprising: a therapeutically effective amount of a compound of formula: wherein A is PO (OR 5), wherein R and R 5 are independently selected from H, C1-C10 alkyl, aryl, aralkyl and X, wherein X is a cationic counterion selected from the group consisting of ammonium, methyl ammonium, dimethylammonium, trimethylammonium, tetramethylammonium, ethanol-ammonium, dicyclohexylammonium, guanidinium, ethylenediammonium cation, lithium cation, sodium cation, potassium cation, cesium cation, beryllium cation, magnesium cation, calcium cation, and zinc cation, wherein B is NHR 6, NH 3 + Y -, R 6 N(C=NH)NH 2 or R 6 N(C=NH 2 +)NH 2 Y -, wherein R 6 represents hydrogen, C1-C10 alkyl, aryl, or aralkyl, wherein Y - is a anionic counterion selected from the group consisting of chloride, bromide, iodide, acetate, trifluoroacetate, phosphate, diphosphate, nitrate, sulphate, benzenesulfonate, benzoate, salicylate, hydroxynaphthoate, fumarate, maleate, lactate, malate, succinate, tartrate, citrate, glutamate, gluconate, and stearate, wherein R 1 is CH 3 or CF 3; wherein R 2 is H, C1-C10 alkyl or O=C-NHR 7, wherein R 7 represents a linker annexed with functional moiety such as biotin, fluorophore and anti-inflammatory agents, and wherein R 3 and R 4 are independently hydrogen, C1-C10 alkyl or O=C-R 8, where R 8 represents C1-C10 alkyl, aryl, or aralkyl; and a pharmaceutically acceptable excipient. a therapeutically effective amount of a compound of formula: wherein A is PO (OR 5), wherein R and R 5 are independently selected from H, C1-C10 alkyl, aryl, aralkyl and X, wherein X is a cationic counterion selected from the group consisting of ammonium, methyl ammonium, dimethylammonium, trimethylammonium, tetramethylammonium, ethanol-ammonium, dicyclohexylammonium, guanidinium, ethylenediammonium cation, lithium cation, sodium cation, potassium cation, cesium cation, beryllium cation, magnesium cation, calcium cation, and zinc cation, wherein B is NHR 6, NH 3 + Y -, R 6 N(C=NH)NH 2 or R 6 N(C=NH 2 +)NH 2 Y -, wherein R 6 represents hydrogen, C1-C10 alkyl, aryl, or aralkyl, wherein Y - is a anionic counterion selected from the group consisting of chloride, bromide, iodide, acetate, trifluoroacetate, phosphate, diphosphate, nitrate, sulphate, benzenesulfonate, benzoate, salicylate, hydroxynaphthoate, fumarate, maleate, lactate, malate, succinate, tartrate, citrate, glutamate, gluconate, and stearate, wherein R 1 is CH 3 or CF 3; wherein R 2 is H, C1-C10 alkyl or O=C-NHR 7, wherein R 7 represents a linker annexed with functional moiety such as biotin, fluorophore and anti-inflammatory agents, and wherein R 3 and R 4 are independently hydrogen, C1-C10 alkyl or O=C-R 8, where R 8 represents C1-C10 alkyl, aryl, or aralkyl; and a pharmaceutically acceptable excipient.
A method for the automated longitudinal guidance of a motor vehicle, comprising: detecting whether two turns (7, 8) are present in an upcoming road section, and if it is detected that two turns (7, 8) are present in the upcoming road section, maintaining a speed of the motor vehicle after passing through a first of the two turns (7, 8) until reaching a second of the two turns (7, 8) at a constant target speed value, wherein the method is characterized in that the detection as to whether two turns (7, 8) are present in the upcoming road section comprises: summing up an angle of the first turn and an angle of the second turn in order to obtain a total angle, comparing the total angle with a threshold value, and detecting that two turns (7, 8) are present in the upcoming road section if the total angle exceeds the threshold value. detecting whether two turns (7, 8) are present in an upcoming road section, and if it is detected that two turns (7, 8) are present in the upcoming road section, maintaining a speed of the motor vehicle after passing through a first of the two turns (7, 8) until reaching a second of the two turns (7, 8) at a constant target speed value, wherein the method is characterized in that the detection as to whether two turns (7, 8) are present in the upcoming road section comprises: summing up an angle of the first turn and an angle of the second turn in order to obtain a total angle, comparing the total angle with a threshold value, and detecting that two turns (7, 8) are present in the upcoming road section if the total angle exceeds the threshold value. summing up an angle of the first turn and an angle of the second turn in order to obtain a total angle, comparing the total angle with a threshold value, and detecting that two turns (7, 8) are present in the upcoming road section if the total angle exceeds the threshold value.
A secondary battery comprising an electrode assembly; a case for accommodating the electrode assembly; a cap plate coupled to the case; and a terminal part (140, 150) that is electrically connected to the electrode assembly and is extended to penetrate through the cap plate, wherein the terminal part (140, 150) comprises a plate-shaped first area (141, 151) having a first thickness that is electrically connected to the electrode assembly from the inside of the case, and a plate-shaped second area (142, 152) having a second thickness and is electrically connected to the first area (141, 151) from the outer side of the case, characterized in that, the second thickness is thicker than the first thickness; the first area is bent in a predetermined shape; and the first area includes a first hook area located at its top end, the second area includes a second hook area located at its bottom end, and the first hook area and the second hook area are coupled to each other. an electrode assembly; a case for accommodating the electrode assembly; a cap plate coupled to the case; and a terminal part (140, 150) that is electrically connected to the electrode assembly and is extended to penetrate through the cap plate, wherein the terminal part (140, 150) comprises a plate-shaped first area (141, 151) having a first thickness that is electrically connected to the electrode assembly from the inside of the case, and a plate-shaped second area (142, 152) having a second thickness and is electrically connected to the first area (141, 151) from the outer side of the case, characterized in that, the second thickness is thicker than the first thickness; the first area is bent in a predetermined shape; and the first area includes a first hook area located at its top end, the second area includes a second hook area located at its bottom end, and the first hook area and the second hook area are coupled to each other.
A modified release tablet formulation comprising: (i) a PDE inhibitor; (ii) one or more of a pharmaceutically acceptable hydrophilic matrix former; and (iii) one or more pharmaceutically acceptable excipients selected from the group consisting of fillers, glidants and lubricants, wherein: the hydrophilic matrix former is present in a concentration from about 10 %w/w to about 30 %w/w hydroxypropyl methylcellulose; the PDE inhibitor is a compound of formula: or a pharmaceutically acceptable salt, or polymorphic forms thereof; and the modified release tablet formulation optionally further comprises a pharmaceutically acceptable coating system. (i) a PDE inhibitor; (ii) one or more of a pharmaceutically acceptable hydrophilic matrix former; and (iii) one or more pharmaceutically acceptable excipients selected from the group consisting of fillers, glidants and lubricants, the hydrophilic matrix former is present in a concentration from about 10 %w/w to about 30 %w/w hydroxypropyl methylcellulose; the PDE inhibitor is a compound of formula: or a pharmaceutically acceptable salt, or polymorphic forms thereof; and the modified release tablet formulation optionally further comprises a pharmaceutically acceptable coating system.
A radiation-curable adhesive composition comprising a base polymer as a principal base material, the base polymer includes structural units derived from at least a monomer A that has a functional group a; a monomer B that is formed from a methacrylate monomer that has an alkyl group that includes at least 10 and no more than 17 carbon atoms; and a monomer C that has both a functional group c that reacts with the functional group a and a polymerizable carbon-carbon double bond group, wherein a number of polymerizable carbon-carbon double bonds introduced into the side chain that derived from the monomer C is at least 7% and no more than 18% of the total number of side chains in the base polymer, and a main chain of the base polymer is configured from the monomer B and the monomer A, the proportion of the monomer B being at least 50 wt% of the total monomers configuring the main chain; and the base polymer includes a polymerizable carbon-carbon double bond group in a side chain as a result of a portion of the functional group a in the monomer A reacting and bonding with the functional group c in the monomer C, wherein the polymer that configures a main chain from structural units derived from the monomer A and the monomer B has a calculated glass transition temperature that is calculated from a Fox equation at no more than 260 K.
A high power wide band-gap MOSFET-gated bipolar junction transistor, "MGT", comprising: a first wide band-gap bipolar junction transistor, "BJT" having a first collector, a first emitter and a first base; a wide band-gap MOSFET having a source region electrically connected to the base of the first wide band-gap BJT and a drain region that is electrically connected to the first collector so that the first BJT and the MOSFET are connected in Darlington configuration and the channel current of the MOSFET provides the base current of the first BJT; a second wide band-gap BJT having a second collector that is electrically connected to the first collector, a second emitter that is electrically connected to the first emitter, and a second base that is electrically connected to the first base, wherein the second base is thinner than the first base so as to provide a non-destructive avalanche current path for the MGT. a first wide band-gap bipolar junction transistor, "BJT" having a first collector, a first emitter and a first base; a wide band-gap MOSFET having a source region electrically connected to the base of the first wide band-gap BJT and a drain region that is electrically connected to the first collector so that the first BJT and the MOSFET are connected in Darlington configuration and the channel current of the MOSFET provides the base current of the first BJT; a second wide band-gap BJT having a second collector that is electrically connected to the first collector, a second emitter that is electrically connected to the first emitter, and a second base that is electrically connected to the first base, wherein the second base is thinner than the first base so as to provide a non-destructive avalanche current path for the MGT.
A lighting device comprising (a) a light source, for producing light source light, and (b) a converter, wherein the converter comprises a matrix of a first polymer, the matrix containing discrete regions comprising a second polymer with luminescent functionality, wherein the second polymer comprises an aromatic polyester comprising luminescent moieties, wherein the first polymer is chemically different from the aromatic polyester, wherein the converter is radiationally coupled to the light source, wherein one or more of the luminescent moieties are part of a backbone of the aromatic polyester and/or wherein one or more of the luminescent moieties are chemically attached to a backbone of the aromatic polyester.
Method for providing an insect-based, low-fat protein meal from an insect-based raw material, the method comprising the steps of: - providing fresh insect-based raw material, which is optionally reduced in size, - pumping the insect-based raw material to a heating step, in which the insect-based raw material is heated to a temperature from 75 to 100°C, - subjecting the heated insect-based raw material to a main centrifugal separation step, in which a light liquid phase comprising a lipid fraction, a heavy liquid phase comprising an aqueous protein-containing fraction and a solid phase are separated to individual streams, - subjecting the solid phase and at least part of the heavy liquid phase, which is optionally concentrated, to a drying step to provide the insect-based, low-fat protein meal, characterized in that at least part of the separated heavy liquid phase is added to the provided insect-based raw material in an amount from 0.01 to 5 kg separated heavy liquid phase / 1 kg of insect-based raw material upstream of the main separation step. - providing fresh insect-based raw material, which is optionally reduced in size, - pumping the insect-based raw material to a heating step, in which the insect-based raw material is heated to a temperature from 75 to 100°C, - subjecting the heated insect-based raw material to a main centrifugal separation step, in which a light liquid phase comprising a lipid fraction, a heavy liquid phase comprising an aqueous protein-containing fraction and a solid phase are separated to individual streams, - subjecting the solid phase and at least part of the heavy liquid phase, which is optionally concentrated, to a drying step to provide the insect-based, low-fat protein meal, characterized in that
An integrated circuit that comprises: a memory unit comprising memory cells, an output port, and read circuitry; and a processing unit; wherein the read circuitry comprises a reduction unit and a first group of in-memory read paths for outputting up to a first number of bits through the output port; and wherein the processing unit is configured to send to the memory unit a read request for reading a second number of bits from the memory unit; characterized in that the reduction unit is configured to control the in-memory read paths, during a read operation triggered by the read request, based on the first number of bits and the second number of bits, and the reduction unit is configured to control irrelevant in-memory read paths when the second number is smaller than the first number, wherein the irrelevant in-memory read paths are associated with irrelevant bits of the first number of bits, and wherein the irrelevant bits are not included in the second number of bits. a memory unit comprising memory cells, an output port, and read circuitry; and a processing unit; wherein the read circuitry comprises a reduction unit and a first group of in-memory read paths for outputting up to a first number of bits through the output port; and wherein the processing unit is configured to send to the memory unit a read request for reading a second number of bits from the memory unit; characterized in that the reduction unit is configured to control the in-memory read paths, during a read operation triggered by the read request, based on the first number of bits and the second number of bits, and the reduction unit is configured to control irrelevant in-memory read paths when the second number is smaller than the first number, wherein the irrelevant in-memory read paths are associated with irrelevant bits of the first number of bits, and wherein the irrelevant bits are not included in the second number of bits.
A binding protein that binds the 5-v8 interface of CD44E comprising: a light chain complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO:1; a light chain complementarity determining region 2 comprising the amino acid sequence of SEQ ID NO:2; a light chain complementarity determining region 3 comprising the amino acid sequence of SEQ ID NO:3; a heavy chain complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO:4; a heavy chain complementarity determining region 2 comprising the amino acid sequence of SEQ ID NO:5; and a heavy chain complementarity determining region 3 comprising the amino acid sequence of SEQ ID NO:6.
A compound of formula or a pharmaceutically acceptable salt thereof, wherein X is CH, Y is C, and Z is N, or X is CH, Y is N, and Z is C, or X is N, Y is N, and Z is C; R 1 is 3,4-dimethoxyphenyl or 1,3-dimethyl-1H-indazol-5-yl; ring A is phenyl, or 5- or 6-membered heteroaryl; m is 0, 1, 2 or 3; each R 2 is independently selected from C1-C6 alkyl, halogen, R 3 O, R 4 R 5 N, R 6 R 7 NS 2, R 8 R 9 NC, R 10 S 2, R 11 S 2 N(R 12), R 13 C O, R 14 C N(R 15), R 16 OC, R 17 C, R 18 C N(R 19)S 2, R 20 OC N(R 21)S 2, CN and -O -; and two R 3, attached to adjacent atoms of ring A, together with the atoms to which they are attached may form a 5- or 6-membered heterocyclic or carbocyclic ring; each R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, R 13, R 14, R 15, R 16, R 17, R 18, R 19, R 20, and R 21 is independently selected from H and C1-C6 alkyl; and any alkyl is optionally substituted by one or more F; for use in the treatment of a Pneumoviridae viral infection. X is CH, Y is C, and Z is N, or X is CH, Y is N, and Z is C, or X is N, Y is N, and Z is C; R 1 is 3,4-dimethoxyphenyl or 1,3-dimethyl-1H-indazol-5-yl; ring A is phenyl, or 5- or 6-membered heteroaryl; m is 0, 1, 2 or 3; each R 2 is independently selected from C1-C6 alkyl, halogen, R 3 O, R 4 R 5 N, R 6 R 7 NS 2, R 8 R 9 NC, R 10 S 2, R 11 S 2 N(R 12), R 13 C O, R 14 C N(R 15), R 16 OC, R 17 C, R 18 C N(R 19)S 2, R 20 OC N(R 21)S 2, CN and -O -; and two R 3, attached to adjacent atoms of ring A, together with the atoms to which they are attached may form a 5- or 6-membered heterocyclic or carbocyclic ring; each R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, R 13, R 14, R 15, R 16, R 17, R 18, R 19, R 20, and R 21 is independently selected from H and C1-C6 alkyl; and any alkyl is optionally substituted by one or more F; for use in the treatment of a Pneumoviridae viral infection.
A capsule having a shell which is a complex of a host and one or more building blocks having suitable host guest functionality thereby to form a supramolecular cross-linked network, wherein the host is cucurbituril, and the one or more building blocks have suitable host guest functionality for the cucurbituril host, wherein a first building block is a polymeric molecule, preferably the polymeric molecule is or comprises a poly(meth)acrylate-, a polystyrene- and/or a poly(meth)acrylamide polymer, and optionally the polymeric molecule comprises a detectable label.